Overview


According to FutureWise analysis the market for vaginitis treatment drug in 2023 is US$ 3.17 billion, and is expected to reach US$ 4.84 billion by 2031 at a CAGR of 5.4%.

Vaginitis causes discharge, itchiness, and pain in the vaginal area. It is most commonly caused by a change in the balance of vaginal flora or an infection. As well as low estrogen levels after menopause, there are some skin conditions that can cause vaginitis. As vaginal infection can be caused by a variety of bacteria and circumstances, treatment depends on the exact cause. It is the most common kind of vaginitis to be caused by bacteria, fungal vaginitis (yeast infection), and trichomoniasis. The treatment of vaginal dryness can be administered in a variety of ways. It is estimated that nearly half of the female population suffers from bacterial vaginosis (BV) without having any symptoms. It has been found that even when asymptomatic, bacterial vaginosis is linked to a high prevalence of pelvic inflammatory illness and endometritis. Since asymptomatic vaginosis makes detection and prevention difficult, the population has little chance of detecting the infection early on. It is predicted that asymptomatic vaginitis will impede the demand for antibiotics and antifungal medicines. It's important to note that if vaginitis isn't treated, it can lead to miscarriages, pre-term births, and, most importantly, an increased chance of contracting HIV. Aside from chlamydia, gonorrhea, and papillomavirus, other STDs associated with vaginitis include chlamydia and gonorrhea. There is also the possibility of infertility occurring at any time. There is a need for treatment for vaginitis based on the aforementioned facts. In addition to OTC drugs, the market for vaginitis treatment drugs also includes prescription medications. "Vaginitis bacteria transplants" are a novel approach to treating vaginitis. As a result, the vaginitis treatment pharmaceuticals market is likely to become more innovative in the coming years.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Vaginitis Treatment Drug Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Vaginitis Treatment Drug Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Abbott Laboratories
  • Baxter International Inc.
  • B. Braun Melsungen AG
  • Allergan AG
  • Johnson and Johnson
  • Prestige Consumer Healthcare, Inc.
  • Sanofi SA
  • Merck and Co Inc.
  • Aurobindo Pharma Limited
  • Mylan NV
  • Sun Pharmaceutical Industries Limited
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd
  • Novartis International AG
  • Cipla Ltd.
  • Bausch and Lomb Incorporated
  • Galderma S.A.
  • Bristol Myers Squibb Company
  • Perrigo Company plc.
  • Lupin Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Inc.
  • Eurofins Scientific SE
  • Apotex Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Type

  • Nitroimidazole Compound
  • Lincosamide Antibiotics
  • Triazoles
  • Imidazoles

By Indication

  • Bacterial Vaginitis
  • Fungal Vaginitis (Yeast Infection)
  • Trichomoniasis

By Route of Administration

  • Oral
  • Cutaneous
  • Vaginal

By Schedule of Drug

  • Prescription Drugs (Rx)
  • Over-the-counter Drugs (OTC)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa


  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Vaginitis Treatment Drug Market By Drug Type, By Indication, By Route of Administration, By Schedule of Drug, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Vaginitis Treatment Drug Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Vaginitis Treatment Drug Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Vaginitis Treatment Drug Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Vaginitis Treatment Drug Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Nitroimidazole Compound
        2. Lincosamide Antibiotics
        3. Triazoles
        4. Imidazoles

  • 8.   Vaginitis Treatment Drug Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Bacterial Vaginitis
        2. Fungal Vaginitis (Yeast Infection)
        3. Trichomoniasis

  • 9.   Vaginitis Treatment Drug Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Cutaneous
        3. Vaginal

  • 10.   Vaginitis Treatment Drug Market, By Schedule of Drug Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Prescription Drugs (Rx)
        2. Over-the-counter Drugs (OTC)

  • 11.   Vaginitis Treatment Drug Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Drug Stores
        4. Mail Order Pharmacies

  • 12.   North America Vaginitis Treatment Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Vaginitis Treatment Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Vaginitis Treatment Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Vaginitis Treatment Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •    1. Abbott Laboratories
               1.1. Company Overview
               1.2. Product Portfolio
               1.3. SWOT Analysis
               1.4. Financial Overview
               1.5. Strategic Overview
         2. Baxter International Inc.
               2.1. Company Overview
               2.2. Product Portfolio
               2.3. SWOT Analysis
               2.4. Financial Overview
               2.5. Strategic Overview
         3. B. Braun Melsungen AG
               3.1. Company Overview
               3.2. Product Portfolio
               3.3. SWOT Analysis
               3.4. Financial Overview
               3.5. Strategic Overview
         4. Allergan AG
               4.1. Company Overview
               4.2. Product Portfolio
               4.3. SWOT Analysis
               4.4. Financial Overview
               4.5. Strategic Overview
         5. Johnson & Johnson
               5.1. Company Overview
               5.2. Product Portfolio
               5.3. SWOT Analysis
               5.4. Financial Overview
               5.5. Strategic Overview          
         6. Prestige Consumer Healthcare, Inc.
               6.1. Company Overview
               6.2. Product Portfolio
               6.3. SWOT Analysis
               6.4. Financial Overview
               6.5. Strategic Overview      
         7. Sanofi SA
               7.1. Company Overview
               7.2. Product Portfolio
               7.3. SWOT Analysis
               7.4. Financial Overview
               7.5. Strategic Overview
         8. Merck & Co Inc.
               8.1. Company Overview
               8.2. Product Portfolio
               8.3. SWOT Analysis
               8.4. Financial Overview
               8.5. Strategic Overview
         9. Aurobindo Pharma Limited
               9.1. Company Overview
               9.2. Product Portfolio
               9.3. SWOT Analysis
               9.4. Financial Overview
               9.5. Strategic Overview
         10. Mylan NV
               10.1. Company Overview
               10.2. Product Portfolio
               10.3. SWOT Analysis
               10.4. Financial Overview
               10.5. Strategic Overview
         11. Sun Pharmaceutical Industries Limited
               11.1. Company Overview
               11.2. Product Portfolio
               11.3. SWOT Analysis
               11.4. Financial Overview
               11.5. Strategic Overview
         12. Pfizer Inc.
               12.1. Company Overview
               12.2. Product Portfolio
               12.3. SWOT Analysis
               12.4. Financial Overview
               12.5. Strategic Overview
         13. Teva Pharmaceutical Industries Ltd
               13.1. Company Overview
               13.2. Product Portfolio
               13.3. SWOT Analysis
               13.4. Financial Overview
               13.5. Strategic Overview
         14. Bayer AG
               14.1. Company Overview
               14.2. Product Portfolio
               14.3. SWOT Analysis
               14.4. Financial Overview
               14.5. Strategic Overview
         15. Dr. Reddy's Laboratories Ltd
               15.1. Company Overview
               15.2. Product Portfolio
               15.3. SWOT Analysis
               15.4. Financial Overview
               15.5. Strategic Overview          
         16. Novartis International AG
               16.1. Company Overview
               16.2. Product Portfolio
               16.3. SWOT Analysis
               16.4. Financial Overview
               16.5. Strategic Overview      
         17. Cipla Ltd.
               17.1. Company Overview
               17.2. Product Portfolio
               17.3. SWOT Analysis
               17.4. Financial Overview
               17.5. Strategic Overview
         18. Bausch & Lomb Incorporated
               18.1. Company Overview
               18.2. Product Portfolio
               18.3. SWOT Analysis
               18.4. Financial Overview
               18.5. Strategic Overview
         19. Galderma S.A.
               19.1. Company Overview
               19.2. Product Portfolio
               19.3. SWOT Analysis
               19.4. Financial Overview
               19.5. Strategic Overview
         20. Bristol Myers Squibb Company
               20.1. Company Overview
               20.2. Product Portfolio
               20.3. SWOT Analysis
               20.4. Financial Overview
               20.5. Strategic Overview
         21. Perrigo Company plc.
               21.1. Company Overview
               21.2. Product Portfolio
               21.3. SWOT Analysis
               21.4. Financial Overview
               21.5. Strategic Overview
         22. Lupin Pharmaceuticals, Inc.
               22.1. Company Overview
               22.2. Product Portfolio
               22.3. SWOT Analysis
               22.4. Financial Overview
               22.5. Strategic Overview
         23. Glenmark Pharmaceuticals Inc.
               23.1. Company Overview
               23.2. Product Portfolio
               23.3. SWOT Analysis
               23.4. Financial Overview
               23.5. Strategic Overview
        24. Eurofins Scientific SE
               24.1. Company Overview
               24.2. Product Portfolio
               24.3. SWOT Analysis
               24.4. Financial Overview
               24.5. Strategic Overview
         25. Apotex Inc.
               25.1. Company Overview
               25.2. Product Portfolio
               25.3. SWOT Analysis
               25.4. Financial Overview
               25.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients